Malignant pleural mesothelioma is a rare and very aggressive cancer with a poor outlook. One cancer treatment has brought hope though. The treatment is known as immune checkpoint inhibitors. There is potential for better outcomes when patients are given this treatment. A new article in Open Respiratory Archives provides a[…]
Latest Immunotherapy Treatments
CAR-T Cell Therapy for Mesothelioma
Mesothelioma is a rare and aggressive cancer mainly caused by asbestos exposure. With the disease being rare, there are limited treatment options for the disease. This is especially true for elderly patients. They can struggle with conventional therapies due to their age and health problems. One therapy known as Chimeric[…]
Drug Factories to Treat Mesothelioma
Researchers from Rice University and Baylor College of Medicine developed a new treatment that can eliminate advanced stage mesothelioma tumors in mice within days. The breakthrough treatment used Rice’s cytokine drug factory implants with a checkpoint inhibitor drug. This combination is showing great potential in mesothelioma preclinical trials. The treatment[…]
Ipilimumab and Nivolumab for the Treatment of Mesothelioma
Mesothelioma is a difficult diagnosis to receive. With this diagnosis comes treatment regimens and their effects on the body. The United Kingdom has a new set of standard treatments for mesothelioma which include Ipilimumab and Nivolumab. A new article in the journal Lung Cancer reviews Ipilimumab and Nivolumab results, using[…]
Keytruda and Chemotherapy Improve Survival in Mesothelioma Patients
The U.S Food and Drug Administration has accepted a priority review for a new Supplemental Biologics License Application. This could be a new era in the management of pleural mesothelioma, leading to a better future for those diagnosed with the cancer. The review is looking for approval of Keytruda used[…]
Immune Checkpoint Inhibitors Can Improve Survival in Mesothelioma Patients
Malignant pleural mesothelioma is a rare cancer that is hard to treat. There is a poor prognosis for people diagnosed with mesothelioma, but there is hope in the form of immune checkpoint inhibitors. There could be a chance of better outcomes in mesothelioma patients. A new article in Open Respiratory[…]
Galinpepimut-S Alongside Opdivo Improves Survival in Mesothelioma Patients
Sellas Life Sciences recently reported results from its Phase I clinical trial showing that survival was improved in pleural mesothelioma patients due to its treatment. The trial looked at the treatment called galinpepimut-S (GPS), an immunotherapy vaccine. There were 10 patients in the study with relapsed or refractory mesothelioma. Nine[…]
Altered CAR-T Cell Therapy for the Treatment of Mesothelioma
Immunotherapy is an innovative and groundbreaking way to treat cancer. It uses the immune system to fight and kill cancer cells. One immunotherapy treatment that is showing good results for certain cancers is called CAR-T cell therapy, which is able to target specific proteins on cancer cells. One of the[…]
Radiation and Immunotherapy Combination Improves Survival in Lung Cancer Patients
A new study looking at low dose radiation and immunotherapy is showing promising results for non-small cell lung cancer. Patients treated with the combination had higher progression free survival compared to patients who received immunotherapy alone. Research was completed at Weill Cornell Medicine, NewYork-Presbyterian as well as at Columbia University[…]
ADI-PEG 20 is Being Tested on Non-Epithelioid Mesothelioma
Polaris Group recently announced an application for a rolling submission of a new mesothelioma treatment. The Biologic License Application is the first step in becoming approved by the Food and Drug Administration. The treatment, known as ADI-PEG 20, is for the use on non-epithelioid mesothelioma patients alongside pemetrexed and platinum[…]
